Related references
Note: Only part of the references are listed.Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
Amelie de Gregorio et al.
BREAST CANCER RESEARCH (2020)
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Elisabeth Trapp et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells
Hsien Liu et al.
BMC CANCER (2019)
Therapeutic approaches for protecting bone health in patients with breast cancer
Diana Lueftner et al.
BREAST (2018)
Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer
Stephanie Strobl et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.
Wolfgang Janni et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Joseph Sparano et al.
JAMA ONCOLOGY (2018)
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
Sukhbinder Dhesy-Thind et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
Jessalyn M. Ubellacker et al.
BREAST CANCER RESEARCH (2017)
Postmenopausal Osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M. Gnant et al.
ANNALS OF ONCOLOGY (2015)
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
被撤回的出版物: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (Retracted article. See vol. 135, pg. 2149, 2021)
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art
M. Clemons et al.
CURRENT ONCOLOGY (2012)
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
C. L. Shapiro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up
I. J. Diel et al.
ANNALS OF ONCOLOGY (2008)
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
M. C. Winter et al.
CANCER TREATMENT REVIEWS (2008)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
T Powles et al.
BREAST CANCER RESEARCH (2006)
Share Paper
